Bio Pharma Dive
JUNE 2, 2024
Study results showed the antibody-drug conjugate helped stave off disease progression better than a standard treatment. But eye-related side effects remained common.
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 2, 2024
The bitter peel of an orange is there to protect the fruit, and it could protect our own insides, too, if only we stopped throwing the rinds away. The zest of oranges has now been found to contain a novel, bioactive compound, called feruloylputrescine (FP), that could benefit heart health when eaten.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 2, 2024
The findings, from a trial testing Imfinzi in limited-stage small cell lung cancer, could help AstraZeneca expand the drug's use.
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 2, 2024
The Central Drugs Standard Control Organisation (CDSCO) has released an updated version of the guidance for Post Approval Changes in Biological Products, regarding the quality, safety and efficacy documents in order to align with the updated standards and digital formats developed after the previous version was rolled out. The new version, the Version 1.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JUNE 2, 2024
The results are a step forward for antibody-drug conjugates, which Enhertu makers AstraZeneca and Daiichi Sankyo see replacing chemo in many tumors.
Pharmaceutical Technology
JUNE 2, 2024
If Enhertu gets approved in the first-line setting metastatic breast cancer setting, 4,200 patients a year could be eligible to receive it.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
JUNE 2, 2024
A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% improvement. | A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% and earned a standing ovation at ASCO 2024.
pharmaphorum
JUNE 2, 2024
ASCO: Gilead sifts lung cancer data for efficacy crumbs Phil.
Fierce Pharma
JUNE 2, 2024
On the eve of the American Society of Clinical Oncology’s annual meeting last week, a piece of news set off vigorous discussions. | After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data.
JAMA Internal Medicine
JUNE 2, 2024
This randomized clinical trial investigates whether long-term use of Jinlida granules decreases the incidence of diabetes in participants with impaired glucose tolerance and multiple metabolic abnormalities.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
JUNE 2, 2024
This chart shows the drugs with the most supplementary protection certificates (SPCs).
Cloudbyz
JUNE 2, 2024
Selecting the right Clinical Trial Management System (CTMS) is crucial for the success of your clinical trials. A robust CTMS not only streamlines trial management but also ensures regulatory compliance, improves data quality, and enhances overall efficiency. Given the complexity and diversity of clinical trials, it is essential to choose a CTMS that aligns with your specific needs and workflows.
Drug Patent Watch
JUNE 2, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five… Source
JAMA Internal Medicine
JUNE 2, 2024
Safe and effective treatments for preventing type 2 diabetes in persons at high risk for the disease are needed. In this issue of JAMA Internal Medicine, Ji and colleagues randomized patients with impaired glucose tolerance and multiple metabolic abnormalities to receive either a traditional Chinese medicine preparation, Jinlida (JLD) granules, 9 g 3 times/d, or placebo.
Drug Patent Watch
JUNE 2, 2024
Brivaracetam is the generic ingredient in two branded drugs marketed by Ucb Inc, Aurobindo Pharma Ltd, Lupin Ltd, Sunshine, and Zydus Pharms and, and is included in seven NDAs.
JAMA Internal Medicine
JUNE 2, 2024
This clinical insights article examines reasons behind the increase in tick-borne diseases and what clinicians should know about diagnosis and mitigation.
FDA Law Blog
JUNE 2, 2024
By Adrienne R. Lenz, Principal Medical Device Regulation Expert — FDA’s Office of Women’s Health (OWH) recently celebrated its 30th anniversary. This office was formed in 1994 to promote the inclusion of women in clinical trials and to provide leadership on topics related to the health of women. Given that FDA was founded in 1906 and the Federal Food, Drug and Cosmetic Act went into effect in 1938, the OWH’s thirty years of existence, while an important milestone, constitutes a very small amou
Expert insights. Personalized for you.
302 
Let's personalize your content